Search
Mutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?
During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.
Read moreLeading Medical Organizations Join Forces Globally to Launch First-Ever World Thrombosis Day
“We must reduce the burden from thrombosis if we are to achieve the World Health Assembly’s global target of reducing mortality from premature non-communicable disease by 25 percent by 2025,” said Gary Raskob, Ph. D.
Read moreEuropean Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.
Meeting Report: European School of Haematology International Conference of Haematological Disorders in the Elderly
The meeting started by reviewing demographic aspects, physiological changes encountered in the elderly, as well as the definition of older and elderly people, frailty and comorbidity.
Read moreThe International Society on Thrombosis and Haemostasis (ISTH) Hosts its Second Advanced Training Course on Thrombosis and Haemostasis on March 13-16, 2014
The Second Advance Training Course is a follow-up to the successful inaugural course organized in 2011 and attended by 200 professionals. Course speakers include nine international and regional experts in the field of thrombosis and haemostasis.
Read moreResearch must provide ‘more good news on outcomes’ while patients need simple and effective information
On behalf of EHA, professor Giovanni Martinelli and professor Theo de Witte spoke of their cutting edge research and the next steps in personalized medicine research in hematology.
Read moreSanquin Blood Supply will culture erythrocytes for transfusion purposes
ABO-Rh-D matched transfusions result in alloimmunisation in 3-5% of recipients. Once allo-immunized, it may become very difficult to find appropriate donor erythrocytes, especially when multiple antibodies or rare combinations of antibodies are present.
Read morePosition of EHA on Access to Medicines
There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.
Position of EHA on Clinical Trials
The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.
Targeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read more